Novel therapeutic avenues in myeloma: Changing the treatment paradigm

ONCOLOGY

Volumn 21, Issue 7, 2007, Pages 785-792

  Ghobrial, Joanne ^a   Ghobrial, Irene M ^a,b   Mitsiades, Constantine ^a   Leleu, Xavier ^a   Hatjiharissi, Evdoxia ^a   Moreau, Anne Sophie ^a   Roccaro, Aldo ^a   Schlossman, Robert ^a   Hideshima, Teru ^a   Anderson, Kenneth C ^a   Richardson, Paul ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; ANTINEOPLASTIC AGENT; AZD 6244; BORTEZOMIB; DEFIBROTIDE; DEHYDRODIDEMNIN B; DEXAMETHASONE; ENZASTAURIN; EVEROLIMUS; IPI 504; KOS 953; LENALIDOMIDE; MELPHALAN; NPI 0052; NSC 639966; NVP LBH589; PERIFOSINE; PLITIDEPSIN; PREDNISONE; RAPAMYCIN; RITUXIMAB; SCIO 469; SGN 40; TEMSIROLIMUS; THALIDOMIDE; TORISEL; TUBACIN; UNCLASSIFIED DRUG; VORINOSTAT; ANGIOGENESIS INHIBITOR; BORONIC ACID DERIVATIVE; DRUG DERIVATIVE; PYRAZINE DERIVATIVE;

ALGORITHM; ANTINEOPLASTIC ACTIVITY; BONE MARROW; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CYTOPENIA; DEEP VEIN THROMBOSIS; DRUG APPROVAL; DRUG MECHANISM; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEART ARRHYTHMIA; HUMAN; LIVER DYSFUNCTION; LOW DRUG DOSE; MULTIPLE MYELOMA; MYALGIA; MYELOMA CELL; NONHUMAN; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SOMNOLENCE; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; THROMBOEMBOLISM; WEAKNESS; DRUG EFFECT; METABOLISM; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HUMANS; MULTIPLE MYELOMA; PYRAZINES; SIGNAL TRANSDUCTION; THALIDOMIDE;

EID: 34948893474     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Kyle RA, Rajkumar SV: Monoclonal gammopathy of undetermined significance. Clin Lymphoma Myeloma 6:102-114, 2005.
2. Kyle RA, Gertz MA, Witzig TE, et al: Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21-33, 2003.
3. Kyle RA, Therneau TM, Rajkumar SV, et al: Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc 79:859-866, 2004.
4. Kumar S, Rajkumar SV, Greipp PR, et al: Cell proliferation of myeloma plasma cells: comparison of the blood and marrow compartments. Am J Hematol 77:7-11, 2004.
5. Rajkumar SV, Kyle RA: Angiogenesis in multiple myeloma. Semin Oncol 28:560-564, 2001.
6. Nowakowski GS, Witzig TE, Dingli D, et al: Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 106:2276-2279, 2005.
7. Greipp PR, San Miguel J, Durie BG, et al: International staging system for multiple myeloma. J Clin Oncol 23:3412-3420, 2005.
8. Fonseca R, Debes-Marun CS, Picken EB, et al: The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 102:2562-2567, 2003.
9. Chng WJ, Fonseca R: Genomics in multiple myeloma: Biology and clinical implications. Pharmacogenomics 6:563-557, 2005.
10. Bergsagel PL, Kuehl WM: Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol Rev 194:96-104, 2003.
11. Hideshima T, Bergsagel PL, Kuehl WM, et al: Advances in biology of multiple myeloma: Clinical applications. Blood 104:607-618, 2004.
12. Kyle RA: Five decades of therapy for multiple myeloma: A paradigm for therapeutic models. Leukemia 19:910-912, 2005.
13. Rajkumar SV, Kyle RA: Thalidomide in the treatment of plasma cell malignancies. J Clin Oncol 19:3593-3595, 2001.
14. Rajkumar SV: Thalidomide: Tragic past and promising future. Mayo Clin Proc 79:899-903, 2004.
15. Hideshima T, Chauhan D, Shima Y, et al: Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96:2943-2950, 2000.
16. Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571, 1999.
17. Ghobrial IM, Rajkumar SV: Management of thalidomide toxicity. J Support Oncol 1:194-205, 2003.
18. Rajkumar SV, Fonseca R, Dispenzieri A, et al: Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 75:897-901, 2000.
19. Weber D, Rankin K, Gavino M, et al: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21:16-19, 2003.
20. Rajkumar SV, Hayman S, Gertz MA, et al: Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20:4319-4323, 2002.
21. Kumar S, Rajkumar SV: Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer 42:1612-1622, 2006.
22. Palumbo A, Bringhen S, Caravita T, et al: Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 367:825-831, 2006.
23. Facon T, Mary, J, Harousseau, J, et al: Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma (abstract 1). J Clin Oncol 24(18S):1s, 2006.
24. Richardson PG, Hideshima T, Anderson KC: Bortezomib (PS-341): A novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 10:361-369, 2003.
25. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003.
26. Richardson PG, Mitsiades C, Hideshima T, et al: Bortezomib: Proteasome inhibition as an effective anticancer therapy. Annu Rev Med 57:33-47, 2006.
27. Richardson PG, Sonneveld P, Schuster MW, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498, 2005.
28. Jagannath S, Barlogie B, Berenson J, et al: A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127:165-172, 2004.
29. Richardson PG, Mitsiades C, Ghobrial I, et al: Beyond single-agent bortezomib: Combination regimens in relapsed multiple myeloma. Curr Opin Oncol 18:598-608, 2006.
30. Anderson K, Richardson P, Chanan-Khan A, et al: Single-agent bortezomib in previously untreated multiple myeloma (MM): Results of a phase II multicenter study (abstract 7504). J Clin Oncol 24(18S):423s, 2006.
31. Jagannath S, Richardson PG, Barlogie B, et al: Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 91:929-934, 2006.
32. Jagannath S, Durie BG, Wolf J, et al: Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 129:776-783, 2005.
33. Harousseau JL, Attal M, Leleu X, et al: Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Results of an IFM phase II study. Haematologica 91:1498-1505, 2006.
34. Mateos MV, Hernandez JM, Hernandez MT, et al: Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 108:2165-2172, 2006.
35. Richardson PG, Mitsiades C, Hideshima T, et al: Lenalidomide in multiple myeloma. Expert Rev Anticancer Ther 6:1165-1173, 2006.
36. Dimopoulos MA, Spencer A, Attal M, et al: Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): Results of a phase 3 study (MM010) (abstract 6). Blood 106:6a, 2005.
37. Weber D, Chen C, Niesvizky M, et al: Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of a North American phase III study (MM-009) (abstract 7521). J Clin Oncol 24(18S):427s, 2006.
38. Rajkumar SV, Hayman SR, Lacy MQ, et al: Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106:4050-4053, 2005.
39. Palumbo A, Falco P, Falcone A, et al: Oral Revlimid plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma: Results of a multicenter phase I/II study (abstract 800). Blood 108:240a, 2006.
40. Chauhan D, Catley L, Li G, et al: A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell 8:407-419, 2005.
41. Hideshima T, Bradner JE, Wong J, et al: Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 102:8567-8572, 2005.
42. Mitsiades CS, Mitsiades NS, McMullan CJ, et al: Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications. Proc Natl Acad Sci U S A 101:540-545, 2004.
43. Richardson P, Schlossman R, Mitsiades C, et al: Phase I clinical trial of oral administration of the histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with relapsed/refractory multiple myeloma (MM) (abstract 1503). Blood 104:420a, 2004.
44. Mitsiades CS, Mitsiades NS, McMullan CJ, et al: Antimyeloma activity of heat shock protein-90 inhibition. Blood 107:1092-1100, 2006.
45. Richardson P, Chanan-Khan A, Alsina M, et al: Safety and activity of KOS-953 in patients with relapsed refractory multiple myeloma (MM): Interim results of a phase 1 trial (abstract 361). Blood 106:109a, 2005.
46. Mitsiades CS, Mitsiades N, Rooney M, et al: IPI-504: A novel hsp90 inhibitor with in vitro and in vivo anti-tumor activity (abstract 2403). Blood 104(11):660a, 2004.
47. Chanan-Khan AA, Richardson PG, Alsina M, et al: Phase I clinical trial of KOS-953 + bortezomib (BZ) in relapsed refractory multiple myeloma (MM) (abstract 362). Blood 106:109a, 2005.
48. Hideshima T, Catley L, Yasui H, et al: Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107:4053-4062, 2006.
49. Richardson P, Lonial S, Jakubowiak J, et al: A multicenter phase II study of perifosine (KRX-0401) alone and in combination with dexamethasone (Dex) for patients with relapsed or relapsed/refractory multiple myeloma (MM) (abstract 3582). Blood 108:1023a, 2006.
50. Mitsiades N, McMullan C, Poulaki V, et al: The mTOR Inhibitor RAD001 (everolimus) is active against multiple myeloma cells in vitro and in vivo (abstract 1496). Blood 104:418a, 2004.
51. Shi Y, Gera J, Hu L, et al: Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 62:5027-5034, 2002.
52. Raje N, Kumar S, Hideshima T, et al: Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 104:4188-4193, 2004.
53. Francis LK, Alsayed Y, Leleu X, et al: Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17- demethoxygeldanamycin has synergistic activity in multiple myeloma. Clin Cancer Res 12:6826-6835, 2006.
54. Podar K, Raab MS, Zhang J, et al: Targeting PKC in multiple myeloma: In vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615. HCl). Blood 109:1669-1677, 2006.
55. Hu L, Shi Y, Hsu JH, et al: Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 101:3126-3135, 2003.
56. Hideshima T, Podar K, Chauhan D, et al: p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene 23:8766-8776, 2004.
57. Siegel D, Krishnan A, Lonial S, et al: Phase II trial of SCIO-469 as monotherapy (M) or in combination with bortezomib (MB) in relapsed refractory multiple myeloma (MM) (abstract 3580). Blood 108:1022a, 2006.
58. Mateos M, Blade J, Prosper F, et al: Preliminary report from an exploratory phase II trial with plitidepsin (Aplidin®) in patients with refractory/relapsed multiple myeloma (abstract 2569). Blood 106, 2005.
59. Schey SA, Fields P, Bartlett JB, et al: Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 22:3269-3276, 2004.
60. Mitsiades C, Benimetskaya L, Menon K, et al: Defibrotide (DF), an orally bioavailable modulator of myeloma tumor-microenvironment interactions: Molecular sequelae and clinical implications (abstract 3523). Blood 108:1005a, 2006.
61. Palumbo A, Rus C, Rossi D, et al: A multi-center phase I/II study of melphalan, prednisone, thalidomide and defibrotide in avanced multiple myeloma patients (abstract 3560). Blood 108:1016a, 2006.
62. Tai YT, Li X, Tong X, et al: Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res 65:5898-5906, 2005.
63. Hussein M, Niesvizky R, Munshi N, et al: A phase I, multi-dose, dose escalation study of SGN-40 (anti-huCD40 mAb) in patients with refractory or recurrent multiple myeloma (abstract 2413). Blood 104:663a, 2004.
64. Hussein M, Berenson J, Niesvizky R, et al: Results of a phase I trial of SGN-40 (anti-huCD40 mAb) in patients with relapsed multiple myeloma (abstract 3576). Blood 108:1021a, 2006.